Validation of plasma Torque Teno viral load applying a CE-certified PCR for risk stratification of rejection and infection post kidney transplantation.

Autor: Görzer I; Center for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria., Haupenthal F; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währiger Gürtel 18-20, 1090 Vienna, Austria., Maggi F; Laboratory of Virology, 'Lazzaro Spallanzani' National Institute for Infectious Diseases, Via Portuense, 292, 00149 Rome, Italy., Gelas F; bioMérieux SA, Centre Christophe Merieux, 5 Rue des Berges, 38024 Grenoble, Cedex 01, France., Kulifaj D; bioMérieux SA, Parc Technologique Delta Sud, 09340, Verniolle, France., Brossault L; bioMérieux SA, 376 Chemin de l'Orme, 69280 Marcy-l'Etoile, France., Puchhammer-Stöckl E; Center for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria., Bond G; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währiger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: gregor.bond@meduniwien.ac.at.
Jazyk: angličtina
Zdroj: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2023 Jan; Vol. 158, pp. 105348. Date of Electronic Publication: 2022 Nov 26.
DOI: 10.1016/j.jcv.2022.105348
Abstrakt: Background: Torque Teno virus (TTV) is non-pathogenic, highly prevalent and reflects the immune status of its host. TTV plasma load was suggested for risk stratification of graft rejection and infection post kidney-transplantation, for which most studies applied an in-house PCR. Recently, a commercial PCR was CE-certified for clinical use. The present study was designed to assess the performance of TTV load as quantified by the commercial PCR in the prediction of graft rejection and infection.
Methods: Patients and events were selected from the prospective TTV-POET trial, including 683 consecutive adult recipients of a kidney-graft transplanted at the Medical University Vienna, 2016-2020. TTV was quantified in plasma drawn in Months 4-12 post-transplant by in-house and commercial PCR and associated with consecutive infections and graft rejections until Month 12 post-transplantation.
Results: A total of 342 samples from 314 patients with 85 biopsies (rejection, n = 18) and 79 infectious events were assessed. The two PCRs were highly associated (estimate 0.91, 95%CI 0.89-0.93), with a mean difference of 1.38 log 10 copies/mL (95%CI 1.46-1.30). The risk of rejection decreased by 25% with every log 10 increase in TTV load as quantified by commercial PCR (RR 0.75, 95%CI 0.67-0.85), and the risk of infection increased by 6% (RR 1.06, 95%CI 1.00-1.12).
Conclusion: These data support the value of TTV quantification by commercial PCR for the risk stratification of graft rejection and infection in the first year post kidney-transplantation. The test performance determined within this study may serve to design clinical trials and subsequently, support application in clinical routine.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Fanny Gelas, Dorian Kulifaj and Ludovic Brossault are employees of bioMérieux.
(Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: